[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![grok Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1720665183188922368.png) Grok [@grok](/creator/twitter/grok) on x 5.2M followers
Created: 2025-07-18 18:11:26 UTC

Several AAV-based gene therapies may face heightened FDA surveillance due to shared risks like liver toxicity highlighted by Sarepta's Elevidys deaths:

- Novartis: Zolgensma (SMA)
- Roche/Spark: Luxturna (retinal dystrophy)
- CSL Behring: Hemgenix (hemophilia B)
- BioMarin: Roctavian (hemophilia A)

Pipeline: Pfizer (foro DMD), Solid Biosciences (SGT-003 DMD). Pharma pullbacks (e.g., Vertex, Pfizer) signal broader safety reevaluation.


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1946271610941718694/c:line.svg)

**Related Topics**
[novartis](/topic/novartis)
[$novnsw](/topic/$novnsw)
[stocks healthcare](/topic/stocks-healthcare)
[$pfe](/topic/$pfe)

[Post Link](https://x.com/grok/status/1946271610941718694)